spacer
home > epc > Autumn 2015
PUBLICATIONS

European Pharmaceutical Contractor

epc
Autumn 2015

   
Text
PDF
bullet
introduction
Editor’s Letter

Graham Hughes touches on this edition's topical talking points: diabetes and obesity, and the big data phenomenon.
 
view
download pdf
bullet
Business and Finance
A CEO’s Worth

Finding a Figurehead


Chris Molloy
at RSA identifies the qualities of biotech leaders that make them such a prized asset, and so integral to attracting investment from within the industry.


 
view
download pdf
Mergers and Acquisitions

Exit This Way


The elevation of CROs has had a knock-on effect on both ends of the pharma spectrum. With mid-tiers eager to expand their ranks, Benchmark International’s Roger Forshaw outlines advice on how smaller specialist firms can capitalise on their commercial value.
 
view
download pdf
bullet
Marketplace & Business
Comparator Drugs

Look Before You Leap

Touching on a grey area of concern to many within the industry, Khaled El-Gendy at Fisher Clinical Services provides a ‘how-to’ guide on seeking out the most appropriate business partner in emerging markets. Never has the phrase ‘it’s all in the planning’ rung truer.


 
view
download pdf
bullet
Legal & Regulatory
Regulatory Pathways

Common Cause

Steffen Thirstrup
from NDA urges pharma companies to adopt a revised and more integrated approach to market entry. The onset of the adaptive pathway provides the perfect opportunity to lose old habits, rightfully placing consumers at the forefront of their focus.
 
view
download pdf
bullet
Drug Development & Delivery
Q&A: Laboratory Technologies

Digesting Data


Munther Baara at Pfizer discusses the current TransCelerate initiatives he is working on – the Shared Investigator Platform and Investigator Registry – and proposes how data can be sensibly managed and utilised to maximise outputs.

 
view
download pdf
bullet
Diabetes Focus
Diabetes Technology

Particle Progress


EPC Industry Advisor Shelley Bowers probes newly tested diagnostic techniques with the potential to treat diabetes on a universal scale. Assessing the practicalities of management, she sees reason to be optimistic about their implementation.

 
view
download pdf
Diabetes and Obesity

Body of Proof


Mohamed El Malt and Vijayanand Rajendran from Europital offer a critical analysis of treatment strategies employed to manage obesity in diabetic patients across both the developing and developed worlds.

 
view
download pdf
bullet
Data Management & IT Solutions
Data Mergers

Big Data Meets Big Pharma

Citing a collection of the 'value-added partnerships' that have arisen in recent times, GlobalData's Adam Dion discusses the broad appeal of big data for life sciences companies. With data analytics and cloud computing continuing to develop, collaborative efforts are sure to become common practice.
 
view
download pdf
bullet
DATA MANAGEMENT
Data Regulation

Big Business

With fresh regulatory proposals along the Brussels pipeline allaying anxieties surrounding data protection, Beverley Flynn at Stevens & Bolton anticipates the imminent embrace of big data within the industry.
 
view
download pdf
Data Presentation

Lost in Translation


Barry Drees of Trilogy denounces the pomposity impeding scientific communication, arguing instead in favour of visual illustration as a means to transmit results into terms easily understood by all.
 
view
download pdf
bullet
Central Labs
Q&A: Central Laboratories

Under the Microscope

Hermann Schulz
of synlab pharma institute (formerly INTERLAB) talks to EPC about the prominence of centralised laboratories and how pharma companies have adjusted to the ever-greater expectations of regulatory authorities.
 
view
download pdf
bullet
Risk Management
Anti-Bribery and Corruption

Held to Account

Heightened US and UK anti-bribery legislation means firms can no longer turn a blind eye to third-party activity in remote places. Ben Higgins at Stroz Freidberg explains why the failure to act accountably is not worth the risk.
 
view
download pdf
Risk Management

Clean Room, Clean Contracts

Matthew Hardwick
and Marcella Stokell from Norton Rose Fulbright take a look at the key issues for developers when seeking to obtain secure projects. Dissecting alternate agreements on the table, they contemplate how different settlements help meet company targets and legal guidelines.
 
view
download pdf
bullet
Review
Event Review: PCMG Conference

Inside Out

EPC Editor Graham Hughes reports back from the recent PCMG Confernce held in Warsaw, divulging the lessons learnt from presentations given by speakers from within and outside of the industry

 
view
download pdf
bullet
In Conclusion
In Conclusion

Well Thought Out

Graham Hughes
applies a cautionary tone to the alleged clinical trial breakthrough for treatment of Alzheimer's disease. He warns that we should not jump the gun while prevention remains the best policy.

 
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Plasticell and GSK sign collaboration agreement to produce hematopoietic cells from iPSCs

Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

Industry Events

Pharmapack Europe 2018

7-8 February 2018, Hall 7.1, Paris Expo, Porte de Versailles, Paris.

As Europe's dedicated Pharmaceutical Packaging and Drug Delivery event, Pharmapack is the industry's go-to place to kick-off the year.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement